Topotecan Gets Expanded Indication for Combined Therapy of Cervical Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 8
Volume 20
Issue 8

The US Food and Drug Administration (FDA) has approved topotecan HCl (Hycamtin) in combination with cisplatin, for the treatment of stage IVB, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Following a 6-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using topotecan in combination with cisplatin compared to cisplatin alone.

The US Food and Drug Administration (FDA) has approved topotecan HCl (Hycamtin) in combination with cisplatin, for the treatment of stage IVB, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Following a 6-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using topotecan in combination with cisplatin compared to cisplatin alone.

Articles in this issue
Erythropoiesis-Stimulating Protein Support and Survival
Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment
Sunitinib Proves Beneficial in Advanced Kidney Cancer, Promising in Lung Cancer
Anastrozole Does Not Cause Osteoporosis in Breast Cancer Patients With Normal Bone Mineral Density at Outset
Capecitabine/Cisplatin Effective in Advanced Gastric Cancer Patients
Bevacizumab/Chemo Combination Approved for Treating Metastatic Colorectal Cancer
The HPV Vaccine: A Model of Research and Prevention
Topotecan Gets Expanded Indication for Combined Therapy of Cervical Cancer
Protein-Bound Paclitaxel Promising as First-Line Treatment in Non-Small-Cell Lung Cancer
Temsirolimus Prolongs Survival of Patients With Advanced Renal Cell Carcinoma
Imatinib Sets New Treatment Standard in Patients With Chronic Myeloid Leukemia
Lapatinib Nearly Doubles Time to Progression for Patients With HER2-Positive Advanced Breast Cancer
Updated Overall Survival Analysis Presented on Sorafenib Trial
Interim Data Suggest Potential Benefits of Darbepoetin Dosed Every 3 Weeks With Intravenous Iron
Integrative Oncology: Principles and Practice
Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Addressing Gaps in Education for Non–Clear Cell RCC

Addressing Gaps in Education for Non–Clear Cell RCC

ONCOLOGY Staff
November 19th 2024
Article

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

BTK Inhibitor Treatment Options Across the Lymphoma Landscape

BTK Inhibitor Treatment Options Across the Lymphoma Landscape

ONCOLOGY Staff
November 17th 2024
Article

Clinicians focused on CLL, follicular lymphoma, and MCL gathered during a Frontline Forum to discuss the use of BTKi in each respective disease state.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Survey Says Gaps Exist in Gynecologic Cancer Treatment

Tim Cortese
November 15th 2024
Article

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.